Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece

被引：0
|
作者：
Charalampos Tzanetakos
Nicholas Tentolouris
Georgia Kourlaba
Nikos Maniadakis
机构：
[1] National School of Public Health,Department of Health Services Organization and Management
[2] National and Kapodistrian University of Athens,First Department of Propaedeutic and Internal Medicine, Medical School
[3] Laiko General Hospital,Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO)
[4] “Aghia Sophia” Children`s Hospital,undefined
来源：
Clinical Drug Investigation | 2016年 / 36卷
关键词：
Metformin; Hypoglycemic Event; Probabilistic Sensitivity Analysis; United Kingdom Prospective Diabetes Study; Drug Acquisition Cost;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：649 / 659
页数：10
相关论文
共 50 条
  • [1] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [2] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [3] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [4] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [5] DAPAGLIFLOZIN: COST EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN ECUADOR
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Sanchez, Solis C.
    Acosta, W.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE NETHERLANDS
    van Haalen, H. G. M.
    Pompen, M.
    Bergenheim, K.
    McEwan, P.
    Townsend, R.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [7] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Kousoulakou, Hara
    Hatzikou, Magdalini
    Baroutsou, Varvara
    Yfantopoulos, John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [8] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Hara Kousoulakou
    Magdalini Hatzikou
    Varvara Baroutsou
    John Yfantopoulos
    Cost Effectiveness and Resource Allocation, 15
  • [9] COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE
    Kousoulakou, H.
    Kalogeropoulou, M.
    Panitti, E.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [10] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
12345